Citations

Mayo Clinic

Showing 10 of 108599 citations.

Survival and Causes of Death Among People With Clinically Diagnosed Synucleinopathies With Parkinsonism
Savica, Rodolfo , Bower, James H., Ahlskog, J. Eric , Graff‐Radford, Jonathan , Rocca, Walter A. , Grossardt, Brandon R. , Boeve, Bradley F. , Mielke, Michelle M.

JAMA Neurology | May 15, 2017 | Volume: 74 | Issue: 7 | Pages: 839

10.1001/jamaneurol.2017.0603 | PMID 28505261 Get It

Image Gallery: A case of pemphigus vulgaris following Simulium spp. (Diptera) bites
Wambier, Carlos Gustavo , Struecker, T.A., Durski, L.N., Wambier, Sarah P.F., Cappel, Mark A. , Vernal, Sebastián , Araújo, A.G. de, Wambier, Sarah Perillo de Farias , Roselino, Ana Maria Ferreira , Wambier, Carlos G

British Journal of Dermatology | May 15, 2017 | Volume: 176 | Issue: 5 | Pages: e100-e100

10.1111/bjd.15393 | PMID 28504401 Get It

Intranuclear and higher‐order chromatin organization of the major histone gene cluster in breast cancer
Fritz, Andrew J. , Ghule, Prachi N. , Tye, Coralee E. , Page, Natalie A., Hong, Deli , Shirley, David J. , Weinheimer, Adam, Gerrard, Diana L., Frietze, Seth , Wijnen, André J. van , Zaidi, Sayyed K. , Imbalzano, Anthony N. , Lian, Jane B. , Stein, Janet L. , van Wijnen, Andre J, Boyd, Joseph R. , Barutcu, A. Rasim , Stein, Gary S. , van Wijnen, Andre J

Journal of Cellular Physiology | May 15, 2017 | Volume: 233 | Issue: 2 | Pages: 1278-1290

10.1002/jcp.25996 | PMID 28504305 Get It

Alterations in nuclear morphology are common in cancer progression. However, the degree to which gross morphological abnormalities translate into compromised higher‐order chromatin organization is poorly understood. To explore the functional links between gene expression and chromatin structure in breast cancer, we performed RNA‐seq gene expression analysis on the basal breast cancer progression model based on human MCF10A cells. Positional gene enrichment identified the major histone gene cluster at chromosome 6p22 as one of the most significantly upregulated (and not amplified) clusters of genes from the normal‐like MCF10A to premalignant MCF10AT1 and metastatic MCF10CA1a cells. This cluster is subdivided into three sub‐clusters of histone genes that are organized into hierarchical topologically associating domains (TADs). Interestingly, the sub‐clusters of histone genes are located at TAD boundaries and interact more frequently with each other than the regions in‐between them, suggesting that the histone sub‐clusters form an active chromatin hub. The anchor sites of loops within this hub are occupied by CTCF, a known chromatin organizer. These histone genes are transcribed and processed at a specific sub‐nuclear microenvironment termed the major histone locus body (HLB). While the overall chromatin structure of the major HLB is maintained across breast cancer progression, we detected alterations in its structure that may relate to gene expression. Importantly, breast tumor specimens also exhibit a coordinate pattern of upregulation across the major histone gene cluster. Our results provide a novel insight into the connection between the higher‐order chromatin organization of the major HLB and its regulation during breast cancer progression.
Reply: Transpulmonary Pressure Meaning: Babel or Conceptual Evolution?
Loring, Stephen H. , Topulos, George P., Hubmayr, Rolf D.

American Journal of Respiratory and Critical Care Medicine | May 15, 2017 | Volume: 195 | Issue: 10 | Pages: 1405-1406

10.1164/rccm.201701-0028le | PMID 28504597 Get It

Learning Health Care System: Pragmatic Comparison of Crystalloid Choice in a Medical Intensive Care Unit
Čubro, Hajrunisa, Kashani, Kianoush , Gajic, Ognjen

American Journal of Respiratory and Critical Care Medicine | May 15, 2017 | Volume: 195 | Issue: 10 | Pages: 1287-1289

10.1164/rccm.201610-2093ed | PMID 28504605 Get It

Editorial: is it time for therapeutic drug monitoring of anti‐TNF agents during pregnancy? Maybe, maybe not
Kane, Sunanda V. , Kane, S

Alimentary Pharmacology & Therapeutics | May 15, 2017 | Volume: 45 | Issue: 12 | Pages: 1555-1556

10.1111/apt.14073 | PMID 28503863 Get It

Linked ContentThis article is linked to Seow et al and Seow papers. To view these articles visit https://doi.org/10.1111/apt.14040 and https://doi.org/10.1111/apt.14093.
Exploratory study of the association of volumetric modulated arc therapy (VMAT) plan robustness with local failure in head and neck cancer
Patel, Samir H. , Harrington, Daniel P. , Hu, Yanle , Ding, Xiaoning, Shen, Jiajian , Halyard, Michele Y. , Wong, William W. , Ezzell, Gary E., Bues, Martin , Schild, Steven E. , Liu, Wei , Shen, Jiajian , Bues, Martin

Journal of Applied Clinical Medical Physics | May 15, 2017 | Volume: 18 | Issue: 4 | Pages: 76-83

10.1002/acm2.12099 | PMID 28503916 Get It

AbstractThis work is to show which is more relevant to cause local failures (LFs) due to patient setup uncertainty between the planning target volume (PTV) underdosage and the potential target underdosage subject to patient setup uncertainties in head and neck (H&N) cancer treated with volumetric‐modulated arc therapy (VMAT). Thirteen LFs in 10 H&N patients treated by VMAT were analyzed. Measures have been taken to minimize the chances of insufficient target delineation for these patients and the patients were clinically determined to have LF based on the PET/CT scan results by an experienced radiologist and then reviewed by a second experienced radiation oncologist. Two methods were used to identify the possible locations of LF due to underdosage: (a) examining the standard VMAT plan, in which the underdosed volume in the nominal dose distribution (UVN) was generated by subtracting the volumes receiving the prescription doses from PTVs, and (b) plan robustness analysis, in which in addition to the nominal dose distribution, six perturbed dose distributions were created by translating the CT iso‐center in three cardinal directions by the PTV margin. The coldest dose distribution was represented by the minimum of the seven doses in each voxel. The underdosed volume in the coldest dose distribution (UVC) was generated by subtracting the volumes receiving the prescription doses in the coldest dose distribution from the volumes receiving the prescription doses in the nominal dose distribution. UVN and UVC were subsequently examined for spatial association with the locations of LF. The association was tested using the binominal distribution and the Fisher's exact test of independence. We found that of 13 LFs, 11 were associated with UVCs (P = 0.011), while three were associated with UVNs (P = 0.99). We concluded that the possible target underdosage due to patient setup uncertainties appeared to be a more relevant factor associated with LF in VMAT for H&N cancer than the compromised PTV coverage at least for the patients included in this study.
Predictors of procedural complications in adult Fontan patients undergoing non-cardiac procedures
Egbe, Alexander C. , Khan, Arooj R., Ammash, Naser M., Barbara, David W. , Oliver, William C., Said, Sameh M. , Akintoye, Emmanuel , Warnes, Carole A. , Connolly, Heidi M.

Heart | May 13, 2017 | Volume: 103 | Issue: 22 | Pages: 1813-1820

10.1136/heartjnl-2016-311039 | PMID 28501797 Get It

Objective Limited data exist regarding the outcomes of non-cardiac procedures (NCPs) in adult patients after Fontan operations (Fontan patients). Methods To compare procedural outcomes after NCPs in Fontan patients with outcomes for two matched control groups: patients with repaired congenital heart disease and biventricular circulation (CHD-BiV) and patients with no heart disease (NHD). We defined cyanosis as oxygen saturation <90% and procedural hypoxia as saturation <80% or a decrease in saturation >10% from baseline. Results There were 538 NCPs in 154 Fontan patients (mean age, 30 years) performed in 1990–2015. Sedation and anaesthesia types were monitored anaesthesia care (256,48%), general anaesthesia (51,9%), minimal sedation (105,20%), local anaesthesia (75,14%) and regional anaesthesia (51,9%). Ninety-three complications occurred in 79 procedures (15%) and included arrhythmia requiring intervention (9), hypotension (14), bradycardia (8), hypoxia (38), heart failure requiring intravenous diuretics (2), acute kidney injury (3), bleeding requiring blood transfusion (1), unplanned procedures for dialysis catheter placement (2), readmission (2), unplanned hospitalisation for hypoxia (8) and unplanned transfer to intensive care unit (1). Baseline cyanosis was the only multivariable risk factor for complications (HR, 1.87 (95% CI 1.14 to 3.67), p=0.04). Procedural complications were more common in the Fontan group (18%) than in the CHD-BiV (5%) and NHD groups (1.4%) (p=0.001). Conclusions Complications after NCPs were more common in Fontan patients, and baseline cyanosis was a risk factor for complications. All-cause mortality was low and may be related to the multidisciplinary care approach used for Fontan patients at our centre.
Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?
Whitwell, Jennifer L. , Höglinger, Günter U. , Antonini, Angelo , Bordelon, Yvette , Boxer, Adam L. , Eimeren, Thilo van , Golbe, Lawrence I. , Kassubek, Jan , Kurz, Carolin , Litvan, Irene , Pantelyat, Alexander , Rabinovici, Gil D. , Respondek, Gesine , Rominger, Axel , Rowe, James B. , Stamelou, María , Josephs, Keith A. , Group, for the Movement Disorder Society‐endorsed PSP Study, Stamelou, Maria , Colosimo, Carlo , Group, for the Movement Disorder Society‐endorsed PSP Study, Höglinger, Günter U , Antonini, Angelo , Rowe, James B , Litvan, Irene , Pantelyat, Alex , Rabinovici, Gil D , van Eimeren, Thilo

Movement Disorders | May 13, 2017 | Volume: 32 | Issue: 7 | Pages: 955-971

10.1002/mds.27038 | PMID 28500751 Get It

ABSTRACTPSP is a pathologically defined neurodegenerative tauopathy with a variety of clinical presentations including typical Richardson's syndrome and other variant PSP syndromes. A large body of neuroimaging research has been conducted over the past two decades, with many studies proposing different structural MRI and molecular PET/SPECT biomarkers for PSP. These include measures of brainstem, cortical and striatal atrophy, diffusion weighted and diffusion tensor imaging abnormalities, [18F] fluorodeoxyglucose PET hypometabolism, reductions in striatal dopamine imaging and, most recently, PET imaging with ligands that bind to tau. Our aim was to critically evaluate the degree to which structural and molecular neuroimaging metrics fulfill criteria for diagnostic biomarkers of PSP. We queried the PubMed, Cochrane, Medline, and PSYCInfo databases for original research articles published in English over the past 20 years using postmortem diagnosis or the NINDS‐SPSP criteria as the diagnostic standard from 1996 to 2016. We define a five‐level theoretical construct for the utility of neuroimaging biomarkers in PSP, with level 1 representing group‐level findings, level 2 representing biomarkers with demonstrable individual‐level diagnostic utility, level 3 representing biomarkers for early disease, level 4 representing surrogate biomarkers of PSP pathology, and level 5 representing definitive PSP biomarkers of PSP pathology. We discuss the degree to which each of the currently available biomarkers fit into this theoretical construct, consider the role of biomarkers in the diagnosis of Richardson's syndrome, variant PSP syndromes and autopsy confirmed PSP, and emphasize current shortfalls in the field. © 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Which ante mortem clinical features predict progressive supranuclear palsy pathology?
Respondek, Gesine , Kurz, Carolin , Arzberger, Thomas, Compta, Yaroslau , Englund, Elisabet , Ferguson, Leslie W. , Gelpí, Ellen , Irwin, David J. , Meissner, Wassilios G. , Pantelyat, Alexander , Rajput, Alex, Swieten, John C. van, Troakes, Claire , Josephs, Keith A. , Lang, Anthony E. , Mollenhauer, Brit , Müller, Ulrich , Whitwell, Jennifer L. , Antonini, Angelo , Bhatia, Kailash P. , Bordelon, Yvette , Corvol, Jean‐Christophe , Dodel, Richard , Kassubek, Jan , Krismer, Florian , Xiong, Chengjie , Lorenzl, Stefan , Morris, Huw R. , Nestor, Peter J. , Oertel, Wolfgang H., Rabinovici, Gil D. , Rowe, James B. , Eimeren, Thilo van , Wenning, Gregor K. , Boxer, Adam L. , Golbe, Lawrence I. , Litvan, Irene , Stamelou, María , Höglinger, Günter U. , Group, for the Movement Disorder Society‐Endorsed PSP Study, Meissner, Wassilios G , Bhatia, Kailash P , Stamelou, Maria , Höglinger, Günter U , Giese, Armin , Nilsson, Christer F. , Swieten, John C. van , Colosimo, Carlo , Grossman, Murray , Krismer, Florian , Group, for the Movement Disorder Society‐Endorsed PSP Study, Lang, Anthony E , Irwin, David J , Antonini, Angelo , Rowe, James B , Corvol, Jean-Christophe , Litvan, Irene , Xiong, Chengjie , Gelpi, Ellen , Pantelyat, Alex , Rabinovici, Gil D , Troakes, Claire , Morris, Huw R , van Eimeren, Thilo

Movement Disorders | May 13, 2017 | Volume: 32 | Issue: 7 | Pages: 995-1005

10.1002/mds.27034 | PMID 28500752 Get It

ABSTRACTBackgroundProgressive supranuclear palsy (PSP) is a neuropathologically defined disease presenting with a broad spectrum of clinical phenotypes.ObjectiveTo identify clinical features and investigations that predict or exclude PSP pathology during life, aiming at an optimization of the clinical diagnostic criteria for PSP.MethodsWe performed a systematic review of the literature published since 1996 to identify clinical features and investigations that may predict or exclude PSP pathology. We then extracted standardized data from clinical charts of patients with pathologically diagnosed PSP and relevant disease controls and calculated the sensitivity, specificity, and positive predictive value of key clinical features for PSP in this cohort.ResultsOf 4166 articles identified by the database inquiry, 269 met predefined standards. The literature review identified clinical features predictive of PSP, including features of the following 4 functional domains: ocular motor dysfunction, postural instability, akinesia, and cognitive dysfunction. No biomarker or genetic feature was found reliably validated to predict definite PSP. High‐quality original natural history data were available from 206 patients with pathologically diagnosed PSP and from 231 pathologically diagnosed disease controls (54 corticobasal degeneration, 51 multiple system atrophy with predominant parkinsonism, 53 Parkinson's disease, 73 behavioral variant frontotemporal dementia). We identified clinical features that predicted PSP pathology, including phenotypes other than Richardson's syndrome, with varying sensitivity and specificity.ConclusionsOur results highlight the clinical variability of PSP and the high prevalence of phenotypes other than Richardson's syndrome. The features of variant phenotypes with high specificity and sensitivity should serve to optimize clinical diagnosis of PSP. © 2017 International Parkinson and Movement Disorder Society